In this exclusive interview, Jean Dietzel, Biome Lead, Germany of Novartis, shares his insights into the of the Covid-19 pandemic on the adoption of digital therapeutics and how digital therapeutics companies should be working with patients to truly deliver to those with unmet medical needs.

Topics covered include:

  • What have we learnt from current national reimbursement schemes and how can we take these learnings forward to complete DTx coverage?
  • How should digital therapeutics companies be working with patients to ensure that these products truly deliver for those with unmet medical needs?
  • What does the future of digital therapeutics look like?

Download your copy here